GCM
ABBV icon

Genus Capital Management’s AbbVie ABBV Stock Holding History

Genus Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,785
Closed -$6.89M – 184
2024
Q4 		$6.89M Sell
38,785
-21,264
-35% -$3.91M 0.94% 30
2024
Q3 		$11.9M Buy
60,049
+25,519
+74% +$4.76M 1.55% 16
2024
Q2 		$5.92M Buy
+34,530
New +$5.72M 0.78% 46

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Genus Capital Management's ABBV Position: Q1 2026 in Review

Genus Capital Management reduced its AbbVie (ABBV) stake by 95% in Q1 2026, selling an estimated $13.3M and leaving 3,498 shares worth $761K. The position accounts for 0.09% of the portfolio, ranked #142.

Genus Capital Management first reported a position in ABBV in Q1 2024 and has held it in 6 quarters since. The position peaked at $14.5M in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Genus Capital Management held 3,498 shares of AbbVie worth $761K as of Q1 2026.
  • Genus Capital Management sold 60,142 AbbVie shares in Q1 2026, an estimated $13.3M.
  • AbbVie made up 0.09% of Genus Capital Management's portfolio in Q1 2026, its #142 holding.
  • Genus Capital Management first reported a position in AbbVie in Q1 2024 and has held it in 6 quarters since.
  • Genus Capital Management's AbbVie position peaked at $14.5M in Q4 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Genus Capital Management's 13F filing for Q1 2026, filed 4 May 2026.